Bill > S01618

This bill establishes the New York Affordable Drug Manufacturing Act, which directs the state's health commissioner to create partnerships aimed at increasing competition and reducing prices for generic prescription drugs. The bill empowers the department of health to enter into agreements with drug manufacturers to produce and distribute generic drugs at lower costs, with a focus on medications for chronic and high-cost conditions. The commissioner must consult with various state agencies, health insurers, hospitals, and other entities to develop a list of targeted drugs, with a requirement that all state agencies purchase generic drugs through these partnerships. The bill mandates specific considerations for drug pricing, including factors like FDA user fees, production costs, and research expenses, and requires transparent pricing without hidden rebates. Additionally, the legislation includes provisions to produce at least one form of insulin and requires the department to submit two key reports to the legislature: one assessing the feasibility of directly manufacturing generic drugs by January 2028, and another analyzing the impact of these partnerships by March 2027. The bill also includes a provision to protect proprietary information obtained during this process from public disclosure, and it will take effect one year after becoming law.

Budget and Finance, Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/S1618